Stay updated on Biomarker Analysis in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Biomarker Analysis in Urothelial Cancer Clinical Trial page.

Latest updates to the Biomarker Analysis in Urothelial Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe clinical trial record for the RESPONDER study is displayed, describing pembrolizumab treatment and biomarker research in urothelial cancer, along with participant criteria, study measures, and record details.SummaryDifference48%

- Check8 days agoChange DetectedThe footer now identifies the site revision as v3.8.0 instead of v3.7.2. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check15 days agoChange DetectedA sitewide NIH notice appears at the top, linking to transition updates and stating that agencies are using “Super Intelligence” in place of “Artificial Intelligence.” The study record itself remains inaccessible behind a 403 error.SummaryDifference1%

- Check22 days agoChange DetectedThe footer’s site revision changed from v3.7.1 to v3.7.2; the study page continues to show a 403 error.SummaryDifference0.2%

- Check29 days agoChange DetectedThe footer revision identifier on the ClinicalTrials.gov 403 Forbidden page changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check50 days agoChange DetectedAccess to the study record now shows a 403 Forbidden error page, replacing the detailed study information. This is an access issue rather than a content update.SummaryDifference18%

Stay in the know with updates to Biomarker Analysis in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Analysis in Urothelial Cancer Clinical Trial page.